Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22470862 | 0.80 | — | — | |
| Trifluoroacetic Acid SCHEMBL1695283 | 0.69 | EZH2 (0.37) | CHEK1PTGDR2KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL1695129 | 0.62 | CHEK1 (0.39) | CHEK1KDM4EMAPK1SMN1; SMN2LMNA | |
| SCHEMBL28789805 | 0.59 | THRA (0.47) | PTGDR2KDM4E | |
| SCHEMBL2591769 | 0.58 | KDM4E (0.36) | CHEK1KDM4E | |
| SCHEMBL29196706 | 0.56 | NR1I2 (0.36) | CHEK1PTGDR2KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL3758554 | 0.55 | PTGDR2 (0.52) | PTGDR2LMNACYP1A2KCNH2 | |
| SCHEMBL5189045 | 0.55 | PTGDR2 (0.42) | PTGDR2KDM4ESMN1; SMN2 | |
| SCHEMBL11457814 | 0.55 | KDM4E (0.43) | PTGDR2KDM4E | |
| SCHEMBL4965313 | 0.55 | KMT2A (0.36) | PTGDR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140343056-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-8637509-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2566479-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343056-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | CHEK1 466/4885PTGDR2 1445/4885KDM4E 682/4885 |
| US-20130059849-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | CHEK1 466/4885PTGDR2 1445/4885KDM4E 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.